Last reviewed · How we verify
Liraglutide treatment 12 weeks
At a glance
| Generic name | Liraglutide treatment 12 weeks |
|---|---|
| Sponsor | Amsterdam UMC, location VUmc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Liraglutide Effect in Atrial Fibrillation (PHASE4)
- Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery (PHASE4)
- SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity (PHASE3)
- Liraglutide Effects on Epicardial Fat Inflammatory Genes (PHASE4)
- Liraglutide Treatment in Obese Infertile PCOS Women (PHASE4)
- Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus (PHASE1, PHASE2)
- LIROH - Liraglutide for Obesity in HIV (PHASE4)
- Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liraglutide treatment 12 weeks CI brief — competitive landscape report
- Liraglutide treatment 12 weeks updates RSS · CI watch RSS
- Amsterdam UMC, location VUmc portfolio CI